Extract
The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mycobacterium tuberculosis complex (Mtbc) isolates challenges tuberculosis (TB) control worldwide [1] and requires the rapid determination of extensive resistance profiles [2], enabling prompt initiation of effective treatment regimens. Phenotypic drug susceptibility testing (pDST) takes up to 6 weeks [3], and is unreliable and/or not standardised for several drugs, according to World Health Organization (WHO) guidelines [4]. Molecular DST (mDST) assays, like Xpert MTB/RIF (Cepheid) or MTBDRplus/sl line probe assays (LPAs; Hain Lifesciences) can be performed directly from clinical specimens, but only target a limited number of resistance variants [5].
Abstract
Targeted next generation sequencing using the Deeplex-MycTB assay can rapidly generate comprehensive drug resistance profiles from Mycobacterium tuberculosis complex cultures and directly from tuberculosis patient samples to guide personalised treatment https://bit.ly/3dP1eIp
Acknowledgements
We thank Tanja Niemann, Vanessa Mohr and Fenja Boysen, Molecular and Experimental Mycobacteriology, Research Centre Borstel, Borstel, Germany, for excellent technical assistance.
Footnotes
Conflict of interest: S. Feuerriegel has nothing to disclose.
Conflict of interest: T.A. Kohl has nothing to disclose.
Conflict of interest: C. Utpatel has nothing to disclose.
Conflict of interest: S. Andres has nothing to disclose.
Conflict of interest: F.P. Maurer has nothing to disclose.
Conflict of interest: J. Heyckendorf has nothing to disclose.
Conflict of interest: A. Jouet reports personal fees from GenoScreen, during the conduct of the study.
Conflict of interest: N. Badalato is an employee of GenoScreen.
Conflict of interest: L. Foray has nothing to disclose.
Conflict of interest: R. Fouad Kamara has nothing to disclose.
Conflict of interest: O.S. Conteh has nothing to disclose.
Conflict of interest: P. Supply reports personal fees for consultancy from Genoscreen, during the conduct of the study.
Conflict of interest: S. Niemann reports grants from German Center for Infection Research, Excellenz Cluster Precision Medicine in Chronic Inflammation EXC 2167 and Leibniz Science Campus Evolutionary Medicine of the LUNG (EvoLUNG), during the conduct of the study.
Support statement: This work was supported by the European Commission (grant: FP7- 278864), Deutsches Zentrum für Infektionsforschung, Joachim Herz Stiftung, Leibniz Science Campus Evolutionary Medicine of the LUNG and Deutsche Forschungsgemeinschaft (grant: Precision Medicine in Chronic Inflammation EXC 216). Funding information for this article has been deposited with the Crossref Funder Registry.
- Received May 1, 2020.
- Accepted June 25, 2020.
- Copyright ©ERS 2021
LIBRARY USERS
Log in through your institution
Purchase access
